Logo for Vincerx Pharma Inc

Vincerx Pharma Investor Relations Material

Latest events

Logo for Vincerx Pharma Inc

Study Update

Vincerx Pharma
Logo for Vincerx Pharma

Q3 2024

12 Nov, 2024
Logo for Vincerx Pharma

Q2 2024

8 Aug, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 11,000+ public companies

Latest reports from Vincerx Pharma Inc

Access all reports
Vincerx Pharma Inc. is a clinical-stage biopharmaceutical company engaged in the development of therapies designed to address unmet medical needs in cancer treatment. Their research focuses on creating new treatment options through the development of drugs like enitociclib, a cyclin-dependent kinase-9 inhibitor currently in clinical trials for patients with hematologic malignancies. Another key area of their research involves VIP236, a small molecule drug conjugate, also in trials, targeting solid tumors. Additionally, Vincerx Pharma is exploring product candidates such as VIP943 and VIP924 for treating hematologic malignancies. The company is headquartered in Palo Alto, California, and its shares are listed on the Nasdaq.